Guggenheim Reiterates Buy on Tarsus Pharmaceuticals, Maintains $46 Price Target
Portfolio Pulse from richadhand@benzinga.com
Guggenheim analyst Eddie Hickman has reiterated a 'Buy' rating on Tarsus Pharmaceuticals (NASDAQ:TARS) and maintained a price target of $46.
August 14, 2023 | 12:38 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Guggenheim's reiteration of a 'Buy' rating and maintenance of a $46 price target for Tarsus Pharmaceuticals could potentially boost investor confidence.
Analyst ratings and price targets can significantly influence investor sentiment and stock prices. In this case, Guggenheim's reiteration of a 'Buy' rating and a $46 price target for Tarsus Pharmaceuticals (TARS) could potentially boost investor confidence and positively impact the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100